Inhaled Nitric Oxide for ARDS-related Pulmonary Hypertension

Overseen by Yuri Matusov, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Yuri Matusov

No Placebo Group

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

Open-label pilot study of early inhaled nitric oxide (iNO) for patients developing de novo pulmonary hypertension during Acute Respiratory Distress Syndrome (ARDS.) The study aims to determine whether iNO has possible hemodynamic and clinical benefits when given early in the course of ARDS to patients with evidence of elevated pulmonary artery pressure.

Research Team

Yuri Matusov, MD

Principal Investigator

Cedars-Sinai Medical Center

Eligibility Criteria

This trial is for patients with ARDS who are starting to show signs of high blood pressure in the lungs. It's open to those who haven't yet received treatment for this specific complication.

Inclusion Criteria

I am 18 years old or older.

Diagnosis of ARDS based on the Berlin criteria

I am on a mechanical ventilator.

Exclusion Criteria

I have been diagnosed with a severe heart condition that affects its ability to pump blood.

I have a serious heart valve condition.

I have a heart condition affecting my heart's muscle.

Treatment Details

Interventions

• Inhaled Nitric Oxide (Vasodilator)

Trial Overview The study tests if inhaling nitric oxide (iNO) early on can help manage increased lung blood pressure and improve overall health in ARDS patients.

Participant Groups

Group I: iNOMAX Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Yuri Matusov

Lead Sponsor

Trials

1

Recruited

20+

Mallinckrodt

Industry Sponsor

Trials

202

Recruited

15,700+

Mario Saltarelli

Mallinckrodt

Chief Medical Officer

MD

Siggi Olafsson

Mallinckrodt

Chief Executive Officer

PhD in Pharmacy